期刊文献+

不同系统检测降钙素原结果的相关性及临床应用符合性分析 被引量:1

Analysis of the correlation among the test results with different procalcitonin systems and the consistency of clinical application
原文传递
导出
摘要 目的评价不同系统上检测的PCT结果的相关性及其在临床应用上的符合性。方法留取在梅里埃VIDAS免疫分析仪上检测浓度在0 ng/ml^200 ng/ml的PCT样本,按不同浓度依次分为1组(0.05 ng/ml^0.50 ng/ml)、2组(0.51 ng/ml^2.00 ng/ml)、3组(2.01 ng/ml^10.00 ng/ml)、4组(>10.00 ng/ml),在美国睿捷Nano-Checker 710免疫层析检测仪上检测PCT。并对两者检测的结果进行相关性和临床应用符合性分析。结果 2台仪器检测的数据总体具有良好的相关性(r=0.961 6),临床应用意义整体符合度为96%(48/50)。在低浓度1组和高浓度4组中,2台仪器的检测结果均具有良好的相关性(r值分别为0.866、0.983)和较高的临床应用意义的符合度(94.11%、100%);在中间浓度的2组和3组,尽管相关系数较低(r值分别为0.389、0.242),但具有较高的临床应用意义符合度(100%、90%)。结论 2台仪器上测量的PCT结果对临床具有相同的应用价值。 Objective To evaluate the correlation of the test results with different detection systems for serum procalcitonin( PCT) and the consistency in clinical application. Methods PCT samples with concentration range at 0 ng/ml- 200 ng/ml by Bio Mérieux VIDAS mini Immunoassay Analyzer were collected,which were also detected with Nano- Checker 710 Immune Chromatography Analyzer,and divided into four groups according to the different concentration: group 1( 0. 05 ng / ml- 0. 50 ng / ml);group 2( 0. 51 ng / ml- 2. 00 ng / ml); group 3( 2. 01 ng / ml- 10. 00 ng / ml); group 4( 10. 00 ng / ml). The results with two detection systems were analyzed on the correlation and compliance of clinical application. Results Data with two detection systems generally had a good correlation( r = 0. 961 6). Conformity degree in clinical application was 96%( 48 /50). In the low concentration group 1 and high concentration group 4,the detection results of the 2 instruments had a good correlation( r =0. 866,0. 983) and higher conformity with clinical significance( 94. 11%,100%); in the intermediate concentration group 2and group 3,although the correlation coefficient was low( r = 0. 389,0. 242),they had a higher consistency with clinical application significance( 100%,90%). Conclusion The test results of PCT showed significance on clinical application between the two detection systems.
作者 颜海洪
出处 《中国卫生检验杂志》 CAS 2016年第7期1000-1002,共3页 Chinese Journal of Health Laboratory Technology
关键词 降钙素原 不同系统 相关性 临床应用符合性 Procalcitonin Different systems Correlation Consistency of clinical application
  • 相关文献

参考文献7

  • 1Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations [J]. Crit Care Med, 2008, 36(3) : 941 -952.
  • 2Christ- Crain M, Muller B. Biomarkers in respiratory tract infec- tions:diagnostic guides to antibiotic prescription, prognostic markers and mediators[J]. Eur Respir J, 2007, 30(3): 556-573.
  • 3Becker KL, Nylen ES, White JC, et al. Procalcitonin and the cal- citonin gene family of peptides in inflammation, infection, and sep- sis:a journey from calcitonin back to its precursors[ J]. J Clin En- docrinol Metab, 2004, 89(4) : 1512 -1525.
  • 4Linscheid P, Seboeck D, Nylen ES, et al. In vitro and in vivo cal- citoninI gene expression in parenchymal cells: a novel product of humanadipose tissue [ J ]. Endocrinology, 2003, 144 ( 12 ) : 5578 - 5584.
  • 5苏翔宇,程璐,邓雨霞,陈燕平,李苏宜,刘琳.血清PCT水平预测成人恶性肿瘤粒细胞缺乏性发热伴感染的荟萃分析[J].山东医药,2013,53(21):78-80. 被引量:5
  • 6徐卫芹.支气管哮喘患儿治疗前后血清hs-CRP、PCT和BNP检测的临床意义[J].放射免疫学杂志,2013,26(4):495-496. 被引量:4
  • 7王世俊,黄伟萍.婴幼儿腹泻时检测PCT的临床意义[J].中国优生与遗传杂志,2011,19(7):125-125. 被引量:1

二级参考文献27

  • 1吴健,李澎.血清降钙素原对危重症患者多器官功能障碍综合征的预测价值[J].中国全科医学,2007,10(12):965-966. 被引量:8
  • 2盛红.支气管哮喘患儿外周血B细胞和T细胞及其亚群的研究[J].放射免疫学杂志,2004,17(4):323-324. 被引量:11
  • 3Mcuruna P, Nedelnikova K, Gurlich R. Physiology and genetics of procalcitonin [ J]. Physiol Res ,2000,49 [ Suppli ] 57 - 65.
  • 4Guibourdenche J,et al. Biochemical markers neonatal sepsis:value of procalcition in the emergency setting [ J ]. Nephrol,2002,17:409.
  • 5Oberhofer M, Vogelsang H, Russwurm S, et al. Outcome prediction by traditional and new markers of inflammation in patients with sepsis. [J]. Clin Chem Lab Med,1999,37(3) :363 -368.
  • 6Dale DC. Colony-stimulating factors for the management of neutro- penia in cancer patients[ J]. Drugs, 2002,62 (Suppl 1 ) :1-15.
  • 7Pascoe J, Steven N. Antibiotics for the prevention of febrile neutro- penia[ J]. Curt Opin Hematol, 2009,16 ( 1 ) :48-52.
  • 8Ruokonen E, Nousiainen T, Pulkki K, et al. Procalcitonin Con- centrations in Patients with Neutropenic Fever[ J]. Eur J Clin Mi- crobiol Infect Dis, 1999,18 ( 4 ) :283-285.
  • 9Antonio J, Adelaida Garcra-Velasco, Olga de! Val, et al. Assess- ment of procalcitonin as a diagnostic and prognostic marker in pa- tients with solid tumors and febrile neutropenia [ J ] Cancer, 2004,100( 11 ) :2462-2469.
  • 10von Lilienfeld-Toal M, Dietrich MP, Glasmacher A, et al. Markers of bacteremia in febrile neutropenic patients with hematological ma- lignancies: procaleitonin and IL-6 are more reliable than C-reactive protein[ J]. Eur J Clin Microbiol Infect Dis, 2004,23 (7) : 539- 544.

共引文献7

同被引文献9

引证文献1

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部